Clinical Trial Update: Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of dasatinib and peg-interferon alfa-2b as first-line therapy for chronic phase chronic myeloid leukemia (CML-CP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Phase Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)
• PEG-Interferon alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Chronic Phase of Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED